Brief Literature Review of History, Undetermined association of Rosiglitazone with Cardiovascular Diseases and Relation with Hepatotoxicity and Weight Gain |
Author(s): |
| Farzana Khan , BRAC University |
Keywords: |
| Rosiglitazone, FDA, Cardiovascular Disease, Hepatotoxicity, Weight Gain |
Abstract |
|
Rosiglitazone is an anti-diabetic drug which reduces insulin sensitivity by activating the formation of insulin-responsive genes by binding to PPARγ receptor by giving agonist activity. Although it has glucose lowering ability, several research outcomes provide data that revealed that it increases the risk of cardiovascular disease based on which use of this drug was restricted. But, several types of research imply no risk of CV associated with the drug and evaluating that, its restriction was lifted. However, it is reported to have other side effects including hepatotoxicity and weight gain. This article summarizes the history of rosiglitazone and discusses the association of cardiovascular disease, hepatotoxicity and weight gain with the rosiglitazone therapy. |
Other Details |
|
Paper ID: IJSRDV5I80213 Published in: Volume : 5, Issue : 8 Publication Date: 01/11/2017 Page(s): 344-346 |
Article Preview |
|
|
|
|
